Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $31.86, signifying a +1.01% move from its prior day's close.

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock of late. Shares of the ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $31.86 which represents a slight increase of $0.32 or 1.01% from the prior close of $31.54. The stock opened at $31.9 and ...

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP-1 drugs while facing potential legal challenges.

Super Bowl ads have hit $8 million each, as advertisers shell out big bucks to get their products in the spotlight. That’s a ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

Millions are expected to tune in to watch the Kansas City Chiefs face off against the Philadelphia Eagles in New Orleans for Super Bowl LIX on Sunday, Feb. 9. Last year’s game, which saw the Chiefs' ...

VC, a venture firm led by Palantir founder Joe Lonsdale, is seeking nearly $1 billion for its sixth fund, according to a ...

Adults with diabetes, heart disease, heart failure, hypertension, or kidney failure may ignore dietary restrictions due to exposure to foods advertised during sporting events.

On K Street, firms linked to a new administration often see their fortunes rise. One of the biggest winners this cycle: Ballard Partners.